<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="120240">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01537549</url>
  </required_header>
  <id_info>
    <org_study_id>IRB1006011088</org_study_id>
    <nct_id>NCT01537549</nct_id>
  </id_info>
  <brief_title>Alpha-lipoic Acid/L-acetyl Carnitine for Progressive Supranuclear Palsy</brief_title>
  <official_title>An Open-label Trial of Alpha-lipoic Acid/L-acetyl Carnitine for Progressive Supranuclear Palsy (PSP): Effect Upon Oxidative Damage and Mitochondrial Biomarkers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Weill Medical College of Cornell University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Weill Medical College of Cornell University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Studies have shown that alpha-lipoic acid and L-acetyl carnitine may have some
      neuroprotective activities and it is hoped that they could be helpful for people with
      neurodegenerative illnesses such as progressive supranuclear palsy (PSP).

      The purpose of this study is to find out whether the nutritional supplement alpha-lipoic
      acid/L-acetyl carnitine is safe and well-tolerated in individuals with PSP when given daily,
      and whether it affects their well-being, brain scan measurements and blood tests that
      measure the energy metabolism in cells.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>December 2011</start_date>
  <completion_date type="Anticipated">December 2013</completion_date>
  <primary_completion_date type="Anticipated">December 2013</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Adverse events</measure>
    <time_frame>at baseline, 4, 12 and 24 weeks</time_frame>
    <description>change of incidence and severity of adverse events</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clinical assessments</measure>
    <time_frame>at baseline, at weeks 5, 13, 25</time_frame>
    <description>changes of scores for UPDRS, Golbe PSP Rating Scale, Hoehn and Yahr Scale and neuropsychological tests</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life</measure>
    <time_frame>at baseline, at weeks 5, 13, 25</time_frame>
    <description>changes of scores for PSP quality of life questionnaire (PSP QOL)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Routine safety laboratory parameters</measure>
    <time_frame>at baseline, at weeks 5, 13, 25</time_frame>
    <description>Changes in
Electrolyte panel (CPT 80051)
Liver function panel (CPT 80076)
CBC (CPT 85027)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cerebral oxidative stress markers</measure>
    <time_frame>at baseline and at week 5</time_frame>
    <description>changes of cerebral lactate and glutathione levels as determined by magnetic resonance spectroscopy</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">15</enrollment>
  <condition>Progressive Supranuclear Palsy</condition>
  <arm_group>
    <arm_group_label>Juvenon</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>alpha-lipoic acid and L-acetyl carnitine</intervention_name>
    <description>alpha-lipoic acid and L-acetyl carnitine capsules, 600mg/1.5g daily for 6 months</description>
    <arm_group_label>Juvenon</arm_group_label>
    <other_name>Juvenon</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of probable PSP by NINDS/PSP workshop criteria (see patient folder)

          -  Age 40-75 years

          -  Able to undergo MRI

          -  Absence of significant medical, psychiatric, and other neurological disease

          -  Stable intake of supplements and medication

        Exclusion Criteria:

          -  Failure to meet probable PSP diagnosis by NINDS/PSP workshop criteria

          -  unable to comply with informed consent process

          -  unable to undergo MRI

          -  presence of significant medical, psychiatric (incl MDD) or other neurological (incl
             epilepsy, brain tumor, stroke) disease

          -  possibility of pregnancy (negative test required in women of childbearing age)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Claire Henchcliffe, MD DPhil</last_name>
    <role>Principal Investigator</role>
    <affiliation>Weill Medical College of Cornell University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Weill Cornell Medical College</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2013</verification_date>
  <lastchanged_date>September 5, 2013</lastchanged_date>
  <firstreceived_date>January 9, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Progressive supranuclear palsy</keyword>
  <keyword>alpha-lipoic acid</keyword>
  <keyword>L-acetyl carnitine</keyword>
  <keyword>antioxidant</keyword>
  <keyword>magnetic resonance spectroscopy</keyword>
  <keyword>neurodegeneration</keyword>
  <keyword>glutathione</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Paralysis</mesh_term>
    <mesh_term>Supranuclear Palsy, Progressive</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Thioctic Acid</mesh_term>
    <mesh_term>Acetylcarnitine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
